TipRanks

Notifications

BTIG Believes Misonix (MSON) Still Has Room to Grow

In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on Misonix (MSONResearch Report), with a price target of $26.00. The company’s shares closed last Thursday at $23.84, close to its 52-week high of $24.42.

According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 29.1% and a 64.1% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Zimmer Biomet Holdings, and Staar Surgical Company.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Misonix with a $24.50 average price target.

See today’s analyst top recommended stocks >>

Misonix’s market cap is currently $417.6M and has a P/E ratio of -20.60. The company has a Price to Book ratio of 40.97.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Misonix, Inc. is a medical device company, which engages in the design, development, manufacture and marketing of therapeutic ultrasonic medical devices. Its products include the bonescalpel cutting system, which is used for surgical procedures of the spine and on maxillofacial procedures; the sonastar surgical aspirator, which is used to emulsify and remove soft and hard tumors; the sonicone wound cleansing and debridement system, which offers tissue specific debridement and cleansing of wounds for effective removal of devitalized tissue and fibrin deposits while sparing viable cells. The company’s ultrasonic medical devices are used in the following surgeries: spine, neuro, orthopedic, wound debridement, cosmetic, laparoscopic, and medical applications. The company was founded by Howard Alliger in 1959 and is headquartered in Farmingdale, NY.

Read More on MSON:

Tags: